Vor Biopharma Inc.

Equities

VOR

US9290331084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-22 pm EDT			5-day change	1st Jan Change
1.715 ^USD	-0.29%		-1.44%	-23.78%

May. 13	Oppenheimer Adjusts Vor Biopharma Price Target to $10 From $15, Maintains Outperform Rating	MT
May. 09	Vor Biopharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Vor Biopharma : ASGCT – 2024 – Poster Presentation 1775

May 10, 2024 at 04:49 pm EDT

May 10, 2024

ASGCT - 2024 - Poster Presentation 1775

Download

Discovery Platform

Gene-Edited Hematopoietic Stem Cells to Enable Next-Generation CAR-T Cell Therapy for the Treatment of AML

VOR_ASGCT_2024_Poster-FINAL

Download

Attachments

Original Link
Permalink

Disclaimer

Vor Biopharma Inc. published this content on 10 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 May 2024 20:48:08 UTC.

Latest news about Vor Biopharma Inc.

Oppenheimer Adjusts Vor Biopharma Price Target to $10 From $15, Maintains Outperform Rating	May. 13	MT
Vor Biopharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Vor Biopharma Inc. Appoints Fouad Namouni as Class II Director	May. 02	CI
Stifel Cuts Price Target on Vor Biopharma to $12 From $15, Maintains Buy Rating	Mar. 21	MT
Oppenheimer Cuts Vor Biopharma Price Target to $15 From $18, Maintains Outperform Rating	Mar. 21	MT
Vor Biopharma Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 20	CI
Vor Biopharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
Vor Biopharma Doses First Blood Cancer Patient With Leukemia Treatment, Provides Cash Runway Guidance	Jan. 17	MT
Vor Bio Doses First AML Patient with VCAR33	Jan. 17	CI
Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference	Nov. 09	CI
Vor Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Vor Bio Announces Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio's Novel eHSC and CAR-T Platform	Nov. 02	CI
Wedbush Cuts Vor Biopharma's Price Target to $11 From $18, Keeps Outperform Rating	23-08-11	MT
Vor Biopharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell Small Cap Comp Value Index	23-06-23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell 3000 Index	23-06-23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell 3000E Index	23-06-23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell Small Cap Completeness Index	23-06-23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell 2500 Index	23-06-23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell 2000 Index	23-06-23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell 3000E Value Index	23-06-23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell 3000 Value Index	23-06-23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell 2000 Value Index	23-06-23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell 2000 Dynamic Index	23-06-23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell 2500 Value Index	23-06-23	CI

Chart Vor Biopharma Inc.

Duration

Period

More charts

Company Profile

Vor Biopharma Inc. is a clinical-stage cell and genome engineering therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Companyâs lead engineered hematopoietic stem cells (eHSC) product candidate include tremtelectogene empogeditemcel (trem-cel), for the treatment for acute myeloid leukemia (AML) and other blood cancers. It is designed to replace the standard of care in transplant settings for patients suffering from acute myeloid leukemia (AML) and other blood cancers. Its VBP101 is a Phase I/II a multicenter, open-label, first-in-human study of trem-cel in patients with AML.

Sector

Biotechnology & Medical Research

Calendar

12:00pm - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.715 USD

Average target price

14.06 USD

Spread / Average Target

+719.97%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VOR BIOPHARMA INC.	-23.78%	117M
MODERNA, INC.	+64.23%	62.59B
IQVIA HOLDINGS INC.	-2.31%	41.18B
LONZA GROUP AG	+43.68%	40.29B
CELLTRION, INC.	-8.29%	27.9B
ICON PUBLIC LIMITED COMPANY	+11.97%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.16%	19.09B
BIO-TECHNE CORPORATION	+7.54%	13.08B
MEDPACE HOLDINGS, INC.	+27.17%	12.05B
UNITED THERAPEUTICS CORPORATION	+25.72%	12.26B

Other Biotechnology & Medical Research